Delcath Systems to Present at Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Delcath Systems (DCTH) announced management will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 4:00 PM (ET). The event provides a platform for showcasing Delcath's focus on treating rare primary and metastatic liver cancers using their investigational product, HEPZATO KIT, designed for high-dose chemotherapy delivery to the liver. While the HEPZATO KIT is not yet FDA-approved, it is marketed in Europe as CHEMOSAT, used in major medical centers. For more details, visit their conference page linked in the announcement.

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at:

• Jefferies Virtual Healthcare Conference on June 3, 2021 at 4:00 PM (ET)
  •  https://wsw.com/webcast/jeff174/dcth/1835973

For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

When is Delcath Systems presenting at the Jefferies Virtual Healthcare Conference?

Delcath Systems will present on June 3, 2021, at 4:00 PM (ET).

What is the focus of Delcath Systems as mentioned in the press release?

Delcath Systems focuses on treating rare primary and metastatic liver cancers.

What product is Delcath Systems highlighting at the conference?

Delcath is highlighting the HEPZATO KIT, an investigational product for high-dose chemotherapy delivery to the liver.

Is the HEPZATO KIT FDA-approved?

No, the HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.

What is the trade name of the system used in Europe?

In Europe, the system is marketed as CHEMOSAT and has been CE Marked.

Who can be contacted for more information about Delcath Systems?

For inquiries, contact Delcath Investor Relations at investorrelations@delcath.com.